Literature DB >> 33982198

Putting Stakeholder Engagement at the Center of Health Economic Modeling for Health Technology Assessment in the United States.

Richard Z Xie1, Erica deFur Malik2, Mark T Linthicum2, Jennifer L Bright2.   

Abstract

While evidence generated from health economic (HE) models is being used more commonly in health technology assessment (HTA) in the US, it is not consistently adopted by different stakeholder groups or across therapeutic areas. We hypothesize that actively engaging with multiple stakeholder groups throughout the model development process may result in models more widely considered by decision makers. To test this hypothesis, the Innovation and Value Initiative has launched a modeling effort to build an open-source HE model focusing on the disease state 'major depressive disorder'. A 20-member advisory group has been formed with representatives from patients, employers, clinicians, innovators, payers, and researchers to guide the model development process. While this effort is still in the early stages, the ongoing stakeholder engagement effort has yielded valuable insights that inform the model design. We have also identified several challenges to implementing this new approach. Our early findings suggest that the stakeholder engagement approach to HE model development has the potential to improve HTA in the US.

Entities:  

Year:  2021        PMID: 33982198     DOI: 10.1007/s40273-021-01036-3

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  5 in total

1.  Health technology assessment in the United States.

Authors:  Bryan Luce; Rebecca Singer Cohen
Journal:  Int J Technol Assess Health Care       Date:  2009-06-09       Impact factor: 2.188

2.  Can We Develop Sustainable and Sharable Cost-Effectiveness Models for Value Assessment in the U.S. Health Care System?

Authors:  Richard H Chapman; Varun Kumar
Journal:  J Manag Care Spec Pharm       Date:  2019-05

3.  Transparency in Health Economic Modeling: Options, Issues and Potential Solutions.

Authors:  Eric Q Wu; Zheng-Yi Zhou; Jipan Xie; Cinzia Metallo; Praveen Thokala
Journal:  Pharmacoeconomics       Date:  2019-11       Impact factor: 4.981

4.  Developing Open-Source Models for the US Health System: Practical Experiences and Challenges to Date with the Open-Source Value Project.

Authors:  Jeroen P Jansen; Devin Incerti; Mark T Linthicum
Journal:  Pharmacoeconomics       Date:  2019-11       Impact factor: 4.981

5.  The Missing Stakeholder Group: Why Patients Should be Involved in Health Economic Modelling.

Authors:  George A K van Voorn; Pepijn Vemer; Dominique Hamerlijnck; Isaac Corro Ramos; Geertruida J Teunissen; Maiwenn Al; Talitha L Feenstra
Journal:  Appl Health Econ Health Policy       Date:  2016-04       Impact factor: 2.561

  5 in total
  4 in total

1.  Four Aspects Affecting Health Economic Decision Models and Their Validation.

Authors:  Talitha Feenstra; Isaac Corro-Ramos; Dominique Hamerlijnck; George van Voorn; Salah Ghabri
Journal:  Pharmacoeconomics       Date:  2021-12-16       Impact factor: 4.981

2.  Developing an Online Infrastructure to Enhance Model Accessibility and Validation: The Peer Models Network.

Authors:  Stephanie Harvard; Amin Adibi; Adam Easterbrook; Gregory R Werker; David Murphy; Don Grant; Alison Mclean; Zhina Majdzadeh; Mohsen Sadatsafavi
Journal:  Pharmacoeconomics       Date:  2022-07-30       Impact factor: 4.558

3.  Factors Limiting Subgroup Analysis in Cost-Effectiveness Analysis and a Call for Transparency.

Authors:  Gemma E Shields; Mark Wilberforce; Paul Clarkson; Tracey Farragher; Arpana Verma; Linda M Davies
Journal:  Pharmacoeconomics       Date:  2021-10-29       Impact factor: 4.981

4.  Preferences for Treatments for Major Depressive Disorder: Formative Qualitative Research Using the Patient Experience.

Authors:  Susan dosReis; Laura M Bozzi; Beverly Butler; Richard Z Xie; Richard H Chapman; Jennifer Bright; Erica Malik; Julia F Slejko
Journal:  Patient       Date:  2022-09-19       Impact factor: 3.481

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.